Fig. 5: Comprehensive inhibition of MCL1, BCL-XL, and BCL-2 is intolerable in vivo. | Cell Death & Disease

Fig. 5: Comprehensive inhibition of MCL1, BCL-XL, and BCL-2 is intolerable in vivo.

From: MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression

Fig. 5: Comprehensive inhibition of MCL1, BCL-XL, and BCL-2 is intolerable in vivo.

a Growth inhibition assessed by the CellTiter-Glo assay of SCLC cell lines treated with navitoclax. Results are expressed as mean ± SEM (N = 5). b Cell viability assay of DMS114, KTOR201, SW1271, and DMS53 treated with S63845 in combination with navitoclax. Results are expressed as mean ± SEM (N = 5). Two-way ANOVA with Tukey’s multiple comparison test demonstrated a significant difference between DMSO and 10 nM navitoclax (*) and between DMSO and 100 nM navitoclax (†) for each S63845 concentration. *,†p < 0.05. c Tumor volume of SCID beige mice bearing DMS53 after treatment with vehicle control (N = 10), S63845 (25 mg/kg, N = 10), navitoclax (10 mg/kg, N = 7), navitoclax (50 mg/kg, N = 6), and S63845 (25 mg/kg) + navitoclax (10 mg/kg, N = 10). Results are expressed as mean ± SEM. Two-way ANOVA with Tukey’s multiple comparison test demonstrated a significant difference between vehicle and navitoclax at 50 mg/kg (‡). d Percent body weight change of SCID beige mice bearing DMS53 during treatment with indicated agents. Results are expressed as mean ± SEM.

Back to article page